SeaStar Medical Holding Corp (NASDAQ:ICU) reported its fourth-quarter and full-year 2025 financial results, delivering a revenue figure that surpassed analyst expectations. The medical device company's stock saw a notable positive reaction in after-market trading following the announcement.
Earnings and Revenue Versus Estimates
The company’s performance for the quarter ending December 31, 2025, showed a mixed picture when measured against Wall Street forecasts. While still reporting a loss, the magnitude was less severe than anticipated.
- Revenue: SeaStar Medical reported Q4 revenue of $420,000. This exceeded the analyst consensus estimate of $376,225, representing a beat of approximately 11.6%.
- Earnings Per Share (EPS): The company reported a non-GAAP loss per share of $0.80. This was notably better than the estimated loss of $1.07 per share, beating expectations by roughly 25%.
For the full year 2025, the company did not provide specific figures in the provided context, but the quarterly beat suggests a positive end to the fiscal period.
Market Reaction and Price Action
The market's immediate response to the earnings release was decisively positive. In after-market trading, shares of SeaStar Medical surged approximately 8.3%. This bullish move stands in contrast to the stock's recent performance, which had seen declines over the past week (-9.7%) and two-week period (-16.7%). The sharp after-hours gain indicates that investors were encouraged by the better-than-expected top and bottom-line results, potentially viewing them as early validation of the company's commercial and operational execution.
Business Highlights from the Press Release
Beyond the financial numbers, SeaStar Medical provided several key business updates that underscore its ongoing commercial and regulatory progress.
- Commercial Expansion: The company announced it has added top-rated children’s hospitals to the customer base for its QUELIMMUNE™ therapy, which is indicated for pediatric Acute Kidney Injury (AKI). This points to growing adoption within a key target market.
- Regulatory Milestone: SeaStar Medical completed enrollment in the FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry. Fulfilling this requirement is a critical step in maintaining the device's market availability and gathering further real-world evidence of its use and effectiveness.
Looking Ahead: Estimates for 2026
While the press release did not provide specific financial guidance for the coming year, analyst estimates offer a glimpse into Wall Street's current expectations. It is important to note that these projections are subject to change.
- Q1 2026 Estimates: Analysts are forecasting a revenue of approximately $378,750 and an EPS loss of $1.07.
- Full-Year 2026 Estimates: For the full year, the current consensus points to revenue of about $2.39 million alongside an expected net loss.
The company's ability to continue beating revenue estimates and potentially narrow its losses will be a focal point for investors as 2026 progresses.
For a detailed look at SeaStar Medical's historical earnings and future analyst projections, you can review the earnings history and analyst estimates.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. Investing involves risk, including the potential loss of principal. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.